Sanofi Targets Acquisitons of as Much as 2 Billion Euros

Sanofi (SAN), France’s largest drugmaker, will target “bolt-on” acquisitions in a price range of 1 billion euros to 2 billion euros, Chief Executive Officer Chris Viehbacher said.

“We will continue to acquire in emerging markets,” Viehbacher said today at the JPMorgan Chase & Co. health-care conference in San Francisco. Viehbacher declined to comment on whether Sanofi is interested in buying Bausch & Lomb, an eye- care company said to be for sale by Warburg Pincus LLC for at least $10 billion.

The Paris-based company still prefers returning cash to shareholders through dividends rather than large share buyback programs, Chief Financial Officer Jerome Contamine said during an appearance with Viehbacher at a question-and-answer session with analysts and investors.

To contact the reporter on this story: Albertina Torsoli in Paris at

To contact the editor responsible for this story: Reg Gale at

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.